<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792464</url>
  </required_header>
  <id_info>
    <org_study_id>2017-02322</org_study_id>
    <nct_id>NCT03792464</nct_id>
  </id_info>
  <brief_title>Serum Hepcidin in Pregnant Women and the Association With Pregnancy Outcome</brief_title>
  <official_title>Serum Hepcidin and Iron Status Parameters in Pregnant Women and the Association With Adverse Maternal and Fetal Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepcidin production is normally upregulated by iron stores, and in obesity has been shown to
      be overexpressed and correlated with low iron status. The increased hepcidin may restrain the
      iron release from the cells by affecting the expression of ferroportin, which probably
      associates with the development of diabetes complication. Firstly, investigator examines the
      difference of serum hepcidin and iron parameters between obese and non-obese pregnant women;
      secondly, the correlation between serum hepcidin and adverse maternal and neonatal outcomes
      in pregnant women will be tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a mono-center, observational, controlled study with 2 parallel groups (obese versus
      non-obese pregnant women). The study will be conducted at the University Hospital of Basel,
      Department of Obstetrics and Antenatal Care. A total of N=188 healthy pregnant women
      (expected 40% with BMI ≥ 30 kg/m2) will be recruited in the first trimester in our
      outpatients` department in order to have a total of 169 evaluable women, considering a
      drop-out rate of 10%. Serum hepcidin, iron and hematological parameters will be measured at
      11-14, 24-28, 32-36 weeks of gestation and at labor. The blood pressure, weight, weight gain,
      BMI and smoking status will be examined at all visits. Blood samples will be measured in the
      University Hospital of Basel, Department of Laboratory Medicine. Recruitment will begin in
      January 2019.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum hepcidin at 11-14 weeks of gestation</measure>
    <time_frame>11-14 weeks of gestation</time_frame>
    <description>serum hepcidin (ng/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum hepcidin at 24-28, 32-36 weeks of gestation and at labor;</measure>
    <time_frame>at 24-28, 32-36 weeks of gestation</time_frame>
    <description>serum hepcidin (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ferritin (µg/l),</measure>
    <time_frame>at 24-28, 32-36 weeks of gestation</time_frame>
    <description>iron status Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRC (%),</measure>
    <time_frame>at 11-14, 24-28, 32-36 weeks of gestation</time_frame>
    <description>blood parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin (g/l),</measure>
    <time_frame>at 11-14, 24-28, 32-36 weeks of gestation</time_frame>
    <description>blood parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>red blood cells (x1012/l),</measure>
    <time_frame>at 11-14, 24-28, 32-36 weeks of gestation</time_frame>
    <description>blood parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematocrit (l/l),</measure>
    <time_frame>at 11-14, 24-28, 32-36 weeks of gestation</time_frame>
    <description>blood parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCV (fl),</measure>
    <time_frame>at 11-14, 24-28, 32-36 weeks of gestation</time_frame>
    <description>blood parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCH (pg),</measure>
    <time_frame>at 11-14, 24-28, 32-36 weeks of gestation</time_frame>
    <description>blood parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCHC (g/l),</measure>
    <time_frame>at 11-14, 24-28, 32-36 weeks of gestation</time_frame>
    <description>blood parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>red blood cell distribution width (%)</measure>
    <time_frame>at 11-14, 24-28, 32-36 weeks of gestation</time_frame>
    <description>blood parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>soluble transferrin receptors (mg/l)</measure>
    <time_frame>at 24-28, 32-36 weeks of gestation</time_frame>
    <description>iron status Parameter</description>
  </secondary_outcome>
  <other_outcome>
    <measure>preeclampsia (presence: yes/no)</measure>
    <time_frame>from 11 week of gestation to the 3 days after the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>pregnancy induced hypertension (presence: yes/no),</measure>
    <time_frame>from 11 week of gestation to the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>infection in pregnancy (presence: yes/no),</measure>
    <time_frame>from 11 week of gestation to the 5 days after the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>anemia (presence: yes/no)</measure>
    <time_frame>from 11 week of gestation to 3 days after the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>iron deficiency (presence: yes/no),</measure>
    <time_frame>from 11 week of gestation to the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>cholestasis in pregnancy (presence:yes/no),</measure>
    <time_frame>from 11 week of gestation to the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>gestational diabetes mellitus (presence: yes/no),</measure>
    <time_frame>from 11 week of gestation to the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>abnormal placentation (presence: yes/no),</measure>
    <time_frame>from 11 week of gestation to the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>blood loss during birth (ml)</measure>
    <time_frame>at the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>transfusion requirement (presence: yes/no)</measure>
    <time_frame>at the birth</time_frame>
    <description>maternal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>gestational age at birth (gestational week and day)</measure>
    <time_frame>at the birth</time_frame>
    <description>neonatal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>birth weight (g)</measure>
    <time_frame>at the birth</time_frame>
    <description>neonatal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>preterm delivery (presence: yes/no)</measure>
    <time_frame>at the birth</time_frame>
    <description>neonatal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>preterm premature rupture of fetal membrane (presence: yes/no)</measure>
    <time_frame>at the birth</time_frame>
    <description>neonatal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>intrauterine growth restriction (yes/no)</measure>
    <time_frame>from 11 week of gestation to the birth</time_frame>
    <description>neonatal outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>intrauterine fetal death</measure>
    <time_frame>from 11 week of gestation to the birth</time_frame>
    <description>neonatal outcome</description>
  </other_outcome>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Anemia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Hematological and serum iron parameters will be determined using routine laboratory
      methodology. Blood samples are collected by venipuncture. All blood measurements will be
      conducted at the University Hospital of Basel, Department of Laboratory Medicine.

      Hb, RBC, HCT, MCV, MCHC, MRC, HRC and CHr are measured using a hematology analyzer. Mean
      corpuscular hemoglobin is automatically calculated from Hb and RBC. Ferritin is assessed by
      chemiluminescence immunoassay and CRP is assessed by immunoturbidimetry. Soluble transferrin
      receptors and serum hepcidin are measured with an ELISA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        188 singleton pregnancies will be recruited in the first trimester at the University
        Hospital of Basel, Department of Obstetrics and Antenatal Care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with a BMI ≥ 18.5 kg/m2,

          -  maternal age ≥ 18 years,

          -  singleton pregnancy,

          -  gestational age at recruitment: 11-14 of gestational weeks,

          -  written informed consent.

        Exclusion Criteria:

          -  pregnant women with a BMI&lt; 18.5 kg/m2,

          -  congenital anomaly of fetus,

          -  severe maternal diseases of heart, liver, kidney, cardiovascular system,
             gastrointestinal tract, neurologic disorders and psychiatric disorders.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Amstad Bencaiova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obsterics, University Hospital of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriela Amstad Bencaiova, MD</last_name>
    <phone>+41 61 556 5922</phone>
    <email>gabriela.amstad@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Amstad Bencaiova, MD, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

